8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): September 2, 2005

                               Immunomedics, Inc.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

            Delaware                   000-12104                61-1009366
  ----------------------------        ------------         -------------------
  (State or Other Jurisdiction        (Commission             (IRS Employer
       of Incorporation)              File Number)         Identification No.)

     300 American Road, Morris Plains, New Jersey                 07950
     --------------------------------------------              ----------
       (Address of Principal Executive Offices)                (Zip Code)

                                (973) 605-8200
              (Registrant's telephone number, including area code)

                                 Not applicable
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425).

[ ]  Soliciting material pursuant to Rule 14A-12 under the Exchange
     Act (17 CFR 240.14a-12).

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b)).

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c)).

================================================================================



ITEM 5.02.     DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
               DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

Effective September 2, 2005, Ivan Horak, M.D. resigned from his position as
Executive Vice President of Research and Development and Chief Scientific
Officer of Immunomedics, Inc. (the "Company"). A copy of the Company's press
release announcing Dr. Horak's resignation is attached hereto as Exhibit 99.1
and incorporated herein by reference.

ITEM 9.01.     FINANCIAL STATEMENTS AND EXHIBITS.

         (c)   EXHIBITS.

         Exhibit No.     Description
         -----------     -------------------------------------------------------
            99.1         Press Release of Immunomedics, Inc. dated September 2,
                         2005.

                                      - 2 -


                                    SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.

                                   IMMUNOMEDICS, INC.

Dated:  September 2, 2005          By:     /s/ Cynthia L. Sullivan
                                           -------------------------------------
                                   Name:   Cynthia L. Sullivan
                                   Title:  President and Chief Executive Officer

                                      - 3 -

EX-99.1

                                                                    Exhibit 99.1

              IMMUNOMEDICS ANNOUNCES CHANGE IN SENIOR MANAGEMENT

    MORRIS PLAINS, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU) today announced Ivan Horak, M.D., the Company's Executive Vice
President of Research and Development and Chief Scientific Officer, has
terminated his employment with the Company.  Dr. Horak has decided to refocus
his career in oncology and the development of small molecules, in which he was
active before joining the company.

    "We are grateful to Dr. Horak for his contributions to our Company over the
last several years, particularly related to the commencement of our Phase III
pivotal trials with epratuzumab in patients with lupus. We now have stronger
preclinical and clinical departments. During the transition, Dr. Horak will
continue to work with the Company on clinical trial activities," stated Cynthia
L. Sullivan, President and Chief Executive Officer.

    "I am very pleased to see the advancement of epratuzumab into pivotal Phase
III trials in the unmet medical need indication for lupus therapy. The novel
mechanisms of action of epratuzumab may provide a significant advantage over
existing therapies. I am confident that the Company's current team will
successfully execute this pivotal program. Furthermore, I am pleased that over
last few years the Company has built a pipeline of novel agents targeting a
broad spectrum of autoimmune diseases and cancer," commented Ivan D. Horak, M.D.

    "With our current clinical, regulatory, and biostatistical teams, as well as
the contracted clinical research organization running the lupus registration
trials, we do not anticipate any delays due to Ivan's departure. It is our
intention to expand our rheumatology and oncology clinical staff to manage our
other Phase I and II clinical studies in these areas. We wish Ivan much success
in his new endeavors," Ms. Sullivan further remarked.

    About Immunomedics

    Immunomedics is a New Jersey-based biopharmaceutical company focused on the
development of monoclonal, antibody-based products for the targeted treatment of
cancer, autoimmune and other serious diseases. We have developed a number of
advanced proprietary technologies that allow us to create humanized antibodies
that can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create highly
targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. Our lead product candidate, epratuzumab, is currently in two pivotal
Phase III trials for the treatment of patients with moderate and severe lupus
(ALLEVIATE A and B). At present, there is no cure for lupus and no new lupus
treatment drug has been approved in the U.S. in the last 40 years. We believe
that our portfolio of intellectual property, which includes approximately 90
patents issued in the United States, and more than 250 other issued patents
worldwide, protects our product candidates and technologies. Visit our web site
at http://www.immunomedics.com.

    This release, in addition to historical information, may contain forward-
looking statements made pursuant to the Private Securities Litigation Reform Act
of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve significant
risks and uncertainties and actual results could differ materially from those
expressed or implied herein. Factors that could cause such differences include,
but are not limited to, risks associated with new product development (including
clinical trials outcome and regulatory requirements/actions), competitive risks
to marketed products and availability of financing and other sources of capital,
as well as the risks discussed in the Company's filings with the Securities and
Exchange Commission. The Company is not under any obligation, and the Company
expressly disclaims any obligation, to update or alter any forward-looking
statements, whether as a result of new information, future events or otherwise.

     For More Information:
     Dr. Chau Cheng
     Associate Director, Investor Relations & Business Analysis
     (973) 605-8200, extension 123
     ccheng@immunomedics.com